David Messenheimer

**** ** **** **. ******** OR ac2iz4@r.postjobfree.com 440-***-****

Objective

Immuno-Oncology scientist position leveraging my I-O expertise to significantly advance the understanding and optimization of immunotherapy combinations from the bench to the clinic Summary

Over five years experience in tumor immunology with a variety of preclinical models, T cell activation assays, and flow cytometry, optimizing therapeutic combinations of tumor vaccines and costimulatory and checkpoint antibodies. Excellent written and oral communications skills with oral presentations at major international meetings. Current Position

Postdoctoral Researcher, in the laboratory of Bernard A. Fox, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA.

Education

2010-2017 Ph.D. Oregon Health & Science University. Program in Molecular and Cellular Biology, Department of Molecular Microbiology and Immunology

(Portland, OR, USA), in the laboratory of Bernard A. Fox at the Earle A. Chiles Research Institute, Providence Cancer Center (Portland, OR, USA) Thesis: Augmenting combination immunotherapies with vaccination or costimulatory/inhibitory antibodies for the treatment of cancer. 1999-2003: B.S. Microbiology and Immunology, University of Rochester (Rochester, NY, USA)

Research Experience

2010-2017

Oregon Health & Science University, Earle A. Chiles Research Institute (Portland, OR USA) Ph.D. Candidate (Tumor Immunology) Laboratory of Bernard A. Fox,

• In collaboration with MedImmune, developed, executed, and analyzed an independently designed project that optimized the immunotherapy combination of T cell costimulation and checkpoint blockade in both transplantable and spontaneous tumor models by identifying a critical role for dosing schedule and timing. This work has drawn significant interest from large Pharma companies.

• Identified and characterized a potential role for GM-CSF in tumor vaccine-primed intratumoral T cell trafficking in preclinical mouse models of sarcomas and melanoma and combination.

• Optimized the combination of autophagosome-enriched vaccines with checkpoint blockade and costimulation in preclinical models.

• Developed projects for, supervised, and mentored summer student fellows

• Coordinated and supervised work with research technicians

• Presented two oral presentations at major international meetings (AACR, AAI) 2008-2010

Colorado State University (Fort Collins, CO USA)

Research Associate II (Vaccine Immunology) Laboratory of Angelo Izzo

• Performed vaccine testing contract work in guinea pig and mouse preclinical models of Mycobacterium tuberculosis infection, testing a wide range of experimental vaccines in Biosafety Level 3 conditions.

2001-2003

University of Rochester (Rochester, NY USA)

Research Associate (Viral Immunology) Laboratory of David Topham

• Studied the role of Very Late Antigen 1 and 2 T cell adhesion molecules in preclinical mouse models of allergic asthma and influenza infection. Honors and Awards

2013-2016: Interactions at the Microbe:Host Interface T32 NIH Training Grant: Oregon Health & Science University

2012-2013: Oregon Clinical Translational Research Institute TL-1 NIH Training Grant: Oregon Health & Science University

2000-2003: Dean’s List: University of Rochester

Teaching Experience

2013-2015 Chest Watch Instructor, Providence Portland Medical Center 2015 Supervisor/Advisor, Summer Fellows Program, Earle A. Chiles Research Institute

Technical Skills

Cell Culture:

Bacterial

Murine tumor cell lines

Murine T-lymphocytes

Lipofection

Flow Cytometry:

12 color panels

In depth phenotyping of lymphocytes

Intracellular cytokine staining

ELISA

ELISPOT

PCR

Animal Handling/Necropsy/Vaccination/Surgery (BSL-3) SDS-PAGE and Western Blot

Thin Layer Chromatography

Multispectral Immunohistochemistry

Publications

Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, and Fox BA. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clinical Cancer Research 2017. Available online.

Feng Z, Jensen SM, Messenheimer DJ, Farhad M, Neuberger M, Bifulco CB, and Fox BA. Multispectral imaging of T and B cells in the murine spleen and tumor. Journal of Immunology 2016. 196:3943-3950

Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS, Gough JM, and Crittenden MR. Optimizing timing of immunotherapy improves control of tumor by hypofractionated radiation therapy. PLoS ONE 2016. DOI:10.1371/journal.pone.0157164

Messenheimer DJ, et al. Multiple vaccinations of GM-CSF-secreting tumor vaccines

(GVAX) protect against tumor challenge and increase T cell tumor trafficking. Manuscript in preparation

Meetings and Presentations

Sequentially targeting upregulated TIM-3 and CTLA-4 does not rescue the attenuated therapeutic efficacy of combination immunotherapy with OX40 costimulation and PD-1 blockade. Society for Immunotherapy of Cancer (SITC) annual meeting, National Harbor, MD, 2016 Poster Presentation

Timing of PD-1 blockade is critical to successful synergy with OX40 costimulation in preclinical mammary tumor models. American Association for Cancer Research (AACR) annual meeting, New Orleans, LA 2016 Oral Presentation

In MCA-induced sarcoma models, booster vaccination with GM-CSF-secreting whole-cell tumor vaccines maintain or improve efficacy but may alter trafficking of tumor-specific T cells. American Association of Immunologists (AAI) annual meeting, New Orleans, LA 2015 Oral Presentation and Poster Presentation

Autophagosome-enriched tumor vaccine combined with costimulation primes effector T cells in a spontaneous murine tumor model, but in combination with costimulation and checkpoint blockade cannot impact tumor burden. Midwinter Conference of Immunologists, Pacific Grove, CA 2014 Poster Presentation

Triple vaccination with MCA-induced sarcomas augments poor efficacy of single vaccination against tumor challenge. TL-1 Grants National Meeting, Rochester, MN 2013 Poster Presentation

References

Available on request

Professional Affiliations

Society for Immunotherapy of Cancer

American Association of Immunologists

American Association for Cancer Research

Contact this candidate